Publicly available records indicate that a class action lawsuit has been filed on behalf of investors in OvaScience (NASDAQ: OVAS) in connection to alleged violations of securities laws by OVAS and certain of its officers. Fitapelli Kurta is interested in hearing from investors who have complaints regarding investments made in OvaScience’s Secondary Offering of 2.3 million shares of common stock between January 8, 2015 and March 26, 2015.
The class action complaint specifically alleges that during the period in question, OVAS’s filing materials might have contained false and/or misleading material information, and/or failed to disclose adverse material information to the public, namely: that about 150 patients who had been subjects, in 2014, of OVAS’s AUGMENT procedure, had not attained a pregnancy success rate that surpassed the rate attained without the procedure. The revelation of these true details caused shares in OVAS to decline in value, according to the complaint, causing harm to investors.
According to the company’s website, OvaScience is “a global fertility company dedicated to improving treatment options for women around the world.” The description continues: “OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States.”
A class action lawsuit has already been filed in connection with OvaScience. If you wish to serve as lead plaintiff in the OVAS lawsuit, you must move the Court no later than May 23, 2017. If you wish to join the litigation, please contact Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery does not require that you serve as a lead plaintiff.